The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. The approval comes following a phase 3 EV-303 trial that…
Pharmacy
Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants. Eli Lilly’s shares peaked Nov. 21, giving the pharmaceutical company market…
On average, oncology accounts for about 70% of hospital drug expenditures, according to IQVIA data covering the U.S. and 11 other countries. Countries approach drug spending in several different ways, clinical research firm IQVIA said in an Oct. 21 report.…
List prices for 10 of the nation’s most expensive drugs will drop to their CMS-negotiated price Jan. 1. House lawmakers introduced a bill Nov. 20 to expand these annual negotiations to 50 medications. Under current law, CMS can negotiate with…
As the U.S. works several levers to lower drug pricing, such as Medicare negotiating costs with drugmakers and President Donald Trump launching TrumpRx, a report from the IQVIA Institute quantified how much more the U.S. pays for medications. IQVIA, a…
Advertisement
In recent weeks, drug manufacturers have announced shortages for several medications. Becker’s compiled a list of recent drug shortages based on data from the American Society of Health-System Pharmacists: 1. Chlorothiazide oral suspensions: Bausch Health has its Diuril oral suspension…
A record-breaking 70% of NYC Health + Hospitals’ primary care patients now have their Type 2 diabetes controlled, the New York City-based system said Nov. 19. NYC Health + Hospitals defines Type 2 diabetes control as an A1C level below…
The Institute for Safe Medication Practices named Altamonte Springs, Fla.-based AdventHealth as a recipient of its annual Cheers Award, which recognizes excellence in medication safety. The health system is receiving the award for its infusion pump management strategy, which has…
Pharmacy’s strategic influence in the C-suite is growing as more executives recognize it not as a cost center, but as a systemwide revenue engine. However, pharmacy leaders say the profession still isn’t fully understood at the executive level, and more…
To manage the finances of CAR-T therapies, which can cost up to $1 million each, health systems are increasingly using “pay for performance” deals, according to a Nov. 17 article in Specialty Pharmacy Continuum. Fran Gregory, PharmD, vice president of…